dc.contributor.author |
Tang, JZ |
en |
dc.contributor.author |
Kong, XJ |
en |
dc.contributor.author |
Kang, J |
en |
dc.contributor.author |
Fielder, GC |
en |
dc.contributor.author |
Steiner, Michael |
en |
dc.contributor.author |
Perry, Johanna |
en |
dc.contributor.author |
Wu, ZS |
en |
dc.contributor.author |
Yin, Z |
en |
dc.contributor.author |
Zhu, T |
en |
dc.contributor.author |
Liu, Dongxu |
en |
dc.contributor.author |
Lobie, Peter |
en |
dc.date.accessioned |
2012-03-04T19:14:18Z |
en |
dc.date.issued |
2010-06 |
en |
dc.identifier.citation |
Molecular Cancer Therapeutics 9(6):1697-1708 Jun 2010 |
en |
dc.identifier.issn |
1535-7163 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/12653 |
en |
dc.description.abstract |
We herein show that Artemin (ARTN), one of the glial cell line-derived neurotrophic factor family of ligands, promotes progression of human non-small cell lung carcinoma (NSCLC). Oncomine data indicate that expression of components of the ARTN signaling pathway (ARTN, GFRA3, and RET) is increased in neoplastic compared with normal lung tissues; increased expression of ARTN in NSCLC also predicted metastasis to lymph nodes and a higher grade in certain NSCLC subtypes. Forced expression of ARTN stimulated survival, anchorage-independent, and three-dimensional Matrigel growth of NSCLC cell lines. ARTN increased BCL2 expression by transcriptional upregulation, and inhibition of BCL2 abrogated the oncogenic properties of ARTN in NSCLC cells. Forced expression of ARTN also enhanced migration and invasion of NSCLC cells. Forced expression of ARTN in H1299 cells additionally resulted in larger xenograft tumors, which were highly proliferative, invasive, and metastatic. Concordantly, either small interfering RNA-mediated depletion or functional inhibition of endogenous ARTN with antibodies reduced oncogenicity and invasiveness of NSCLC cells. ARTN therefore mediates progression of NSCLC and may be a potential therapeutic target for NSCLC. |
en |
dc.publisher |
American Association for Cancer Research |
en |
dc.relation.ispartofseries |
Molecular Cancer Therapeutics |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from: http://www.sherpa.ac.uk/romeo/issn/1535-7163/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2 |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1158/1535-7163.MCT-09-1077 |
en |
pubs.issue |
6 |
en |
pubs.begin-page |
1697 |
en |
pubs.volume |
9 |
en |
dc.rights.holder |
Copyright: American Association for Cancer Research |
en |
dc.identifier.pmid |
20530713 |
en |
pubs.author-url |
http://mct.aacrjournals.org/content/9/6/1697.full.pdf+html |
en |
pubs.end-page |
1708 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
192837 |
en |
pubs.org-id |
Liggins Institute |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2010-12-06 |
en |
pubs.dimensions-id |
20530713 |
en |